Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ERN1 | O75460 | 7/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31535483 | 0.91 | ESR2 (0.44) | ESR2ERN1NR1H2MTHFD2ADORA1 | |
| SCHEMBL20209038 | 0.85 | MTHFD2 (0.46) | ESR2NR1H2MTHFD2KDM4EALDH1A1 | |
| SCHEMBL21354141 | 0.85 | MTHFD2 (0.45) | ESR2ESR1ERN1MTHFD2KDM4E | |
| SCHEMBL20208675 | 0.84 | KDM4E (0.36) | ESR2NR1H2MTHFD2KDM4EALDH1A1 | |
| SCHEMBL20208677 | 0.82 | MTHFD2 (0.37) | ESR2NR1H2MTHFD2KDM4EALDH1A1 | |
| SCHEMBL30038086 | 0.82 | MTHFD2 (0.37) | ESR2NR1H2MTHFD2KDM4EALDH1A1 | |
| SCHEMBL20208562 | 0.82 | KDM4E (0.55) | ESR2ERN1MTHFD2KDM4EALDH1A1 | |
| SCHEMBL20209037 | 0.80 | MTHFD2 (0.47) | ESR2MTHFD2P2RX3 | |
| SCHEMBL15503188 | 0.80 | ESR2 (0.51) | ESR2NR1H2KDM4EADORA1PARP1 | |
| SCHEMBL31535260 | 0.77 | MTHFD2 (0.39) | MTHFD2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-3546463-B1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO CO LTD (JP) | 2022-12-07 | — | — | EP | disclosed |
| EP-3546463-B1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO CO LTD (JP) | 2022-12-07 | — | — | EP | disclosed |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-3546463-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | Daiichi Sankyo Co., Ltd. (JP) | 2019-10-02 | — | — | EP | disclosed |
| EP-3546463-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | Daiichi Sankyo Co., Ltd. (JP) | 2019-10-02 | — | — | EP | disclosed |
| US-20190284198-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20190284198-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2018097162-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | 第一三共株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284198-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | MTHFD1, MTHFD2, DHFR | ESR2 3216/4885ESR1 3494/4885ERN1 2490/4885 |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | MTHFD1, MTHFD2, DHFR | ESR2 3216/4885ESR1 3494/4885ERN1 2490/4885 |
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | ESR2 134/4885ESR1 482/4885ERN1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.